Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Product Type
  5. Peptide Therapeutic

Peptide Therapeutic

Evaluate

Thumbnail
March 04, 2019

Lilly takes a leaf out of Mylan’s book to defuse insulin price complaints

Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.

Thumbnail
February 12, 2019

Asco-GU 2019 – Nektar gets that sinking feeling again

Article image
Vantage logo
February 07, 2019

Novo Nordisk sticks its neck out for a tech that promises oral insulin

A capsule device inspired by the shape of a tortoise’s shell might just be able to deliver proteins orally, and Novo Nordisk is on board. But the tech is still years away…

Article image
Vantage logo
February 01, 2019

Upcoming events – Ascendis and Lilly hope for growth with pivotal data

Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.

Article image
Vantage logo
October 05, 2018

Lilly shows that innovation in diabetes is not dead yet

Article image
Vantage logo
August 07, 2018

Protagonist will need more than perseverance to play in bowel disease

A new analysis of an abandoned trial has resurrected Protagonist's lead asset, but the company has a long way to go and faces some stiff competition.

Article image
Vantage logo
May 24, 2018

Why competitive bidding will be a hard task in Medicare

The US government is trying to change the way Medicare reimburses doctors for office-administered drugs – but whether it will succeed is another story.

Vantage logo
March 27, 2018

Protagonist waits to find out the meaning of trial failure

Article image
Vantage logo
March 07, 2018

Heart benefit now a baseline for Invokana and all diabetes drugs

Invokana looking for good showing at American College of Cardiology meeting to improve prospects.

Vantage logo
February 20, 2018

Interview – Rani’s pill injector promises much, but is still preclinical

Article image
Vantage logo
November 09, 2017

Slowing Acthar sales are a warning about rising patient costs

Acthar's high price tag has led to slowing sales, but it is patients, not payers, who are leading the backlash.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up